DexCom: Continuous Glucose Monitoring & Diabetes Tech Platform

A Dexcom G6 transmitter. DexCom, Inc. (Nasdaq: DXCM) builds continuous glucose monitoring systems around recurring sensor and transmitter usage.

DexCom, Inc. (Nasdaq: DXCM) is a San Diego, California–headquartered medical device company and the global leader in continuous glucose monitoring (CGM) technology. Founded in 1999, Dexcom has pioneered real-time glucose biosensing for over 25 years, enabling people with diabetes to track their glucose levels continuously through a small wearable sensor — eliminating the need for routine fingerstick blood tests. In FY2025, Dexcom reported revenue of $4.662 billion (+16% YoY), and in Q1 2026, revenue grew 15% to $1.192 billion with significant margin expansion.

This article explains Dexcom's CGM technology, recurring-revenue business model, product portfolio, market expansion strategy, and competitive positioning. This is not investment advice. It is an educational overview of the business behind the ticker.

Company History

Dexcom was founded in 1999 in San Diego, California, with the mission of developing a practical, real-time continuous glucose monitoring system. The company's founding insight was that people with diabetes needed continuous, actionable glucose data — not just periodic snapshots from fingerstick tests.

Key milestones:

• 1999 — Founded in San Diego, California
• 2005 — IPO on Nasdaq (ticker: DXCM)
• 2006 — FDA approval of first CGM system (STS)
• 2012–2015 — Dexcom G4 and G5 generations established CGM as standard of care for Type 1 diabetes
• 2018 — Dexcom G6 launched: factory-calibrated, no fingersticks required, 10-day wear
• 2023 — Dexcom G7 launched: smaller sensor, faster warm-up, integrated transmitter
• 2024 — Stelo launched: first OTC CGM biosensor for people with Type 2 diabetes not on insulin
• 2025 — FY2025 revenue reached $4.662 billion (+16% YoY)
• Q1 2026 — G7 15 Day expanded across all U.S. channels; Dexcom Flex introduced for Type 2 diabetes

Business Model: Recurring Revenue Biosensing

Dexcom operates a razor/blade recurring revenue model. The CGM system consists of a small disposable sensor (replaced every 10–15 days) and a reusable transmitter, paired with a smartphone app or dedicated receiver. Key characteristics:

• Recurring consumable revenue — sensors are replaced every 10–15 days, creating predictable, high-frequency repeat purchases for each active user
• Prescription + OTC channels — traditional CGM (G7) is prescribed and reimbursed by insurance; Stelo is available over-the-counter for broader market access
• Software ecosystem — Dexcom Clarity cloud platform provides analytics, pattern recognition, and data sharing with healthcare providers, increasing switching costs
• Global distribution — sold in 45+ countries through distributors and direct channels; international revenue growing faster than U.S.
• Reimbursement-driven adoption — Medicare, Medicaid, and commercial insurance coverage expansion drives new patient starts
• Manufacturing scale — vertically integrated sensor manufacturing with capacity expansion to support growing user base

Products & Technology

Dexcom's product portfolio spans the full spectrum of glucose monitoring needs:

• Dexcom G7 — flagship CGM for Type 1 and Type 2 diabetes on insulin. 60% smaller than G6, 30-minute warm-up, 10-day wear, integrated transmitter, real-time alerts and sharing
• Dexcom G7 15 Day — extended-wear version of G7 with 15-day sensor life, reducing cost per day and sensor change frequency. Expanded across all U.S. channels in Q1 2026
• Stelo — first OTC glucose biosensor. Designed for adults with Type 2 diabetes not on insulin and general wellness users. No prescription required. Expands total addressable market significantly
• Dexcom Flex — introduced for adults with Type 2 diabetes not on insulin therapy, with clinical evidence showing significant A1C improvement
• Dexcom ONE — value-tier CGM for international markets, providing core glucose monitoring at accessible price points
• Dexcom Clarity — cloud-based analytics platform for patients and clinicians. Provides glucose pattern analysis, time-in-range metrics, and remote monitoring capabilities
• Sensor technology — proprietary electrochemical biosensing platform using glucose oxidase enzyme on a thin-film electrode, measuring interstitial fluid glucose every 5 minutes

Market Opportunity & Expansion

Dexcom's addressable market is expanding from its traditional Type 1 diabetes base into much larger populations:

• Type 1 diabetes — ~8.5 million people globally; Dexcom's core market with high penetration rates in developed markets
• Type 2 diabetes on insulin — ~30+ million people globally; growing adoption as CGM demonstrates improved outcomes and cost savings
• Type 2 diabetes not on insulin — ~400+ million people globally; massive expansion opportunity via Stelo (OTC) and Dexcom Flex. Clinical evidence from ATTD 2026 shows significant A1C improvement
• General wellness — metabolic health tracking for non-diabetic users interested in glucose response to diet and exercise
• Geographic expansion — international revenue grew 26% YoY in Q1 2026 (reported), with strong growth in Europe, Asia-Pacific, and emerging markets

The shift from Type 1–only to the broader Type 2 and wellness markets represents a potential 10x+ expansion of Dexcom's addressable population.

Financial Profile

FY2025 highlights (year ended December 31, 2025):

• Revenue: $4.662 billion (+16% YoY reported, +15% organic)
• U.S. revenue: +15% YoY; International revenue: +16% reported (+15% organic)
• GAAP operating income: $911.8 million (19.6% of revenue, +470 bps YoY)
• Non-GAAP operating income: $969.3 million (20.8% of revenue, +200 bps YoY)
• Q4 2025 revenue: $1.260 billion (+13% YoY)
• Q4 2025 GAAP operating margin: 25.6% (+860 bps YoY)

Q1 2026 highlights (quarter ended March 31, 2026):

• Revenue: $1.192 billion (+15% YoY reported, +12% organic)
• U.S. revenue: $832.3 million (+11% YoY); International: $359.6 million (+26% YoY)
• GAAP gross margin: 62.9% (vs 56.9% in Q1 2025, +600 bps YoY)
• Non-GAAP gross margin: 63.5% (vs 57.5% in Q1 2025)
• GAAP operating income: $255.3 million (21.4% of revenue, +850 bps YoY)
• GAAP net income: $199.5 million; diluted EPS: $0.51 (vs $0.27 in Q1 2025)
• Non-GAAP diluted EPS: $0.56 (vs $0.32 in Q1 2025, +75% YoY)
• Adjusted EBITDA: $364.5 million (30.6% margin, vs 22.2% in Q1 2025)
• Cash, cash equivalents, and marketable securities: $2.42 billion

2026 guidance (reaffirmed/raised April 30, 2026): Revenue $5.16–$5.25 billion (11–13% growth). Non-GAAP gross margin ~63–64%. Non-GAAP operating margin ~23–23.5% (raised). Adjusted EBITDA margin ~31–31.5% (raised). Additionally, a $1.0 billion share repurchase program was announced at the 2026 Investor Day.

Key Risks

• Competition — Abbott's FreeStyle Libre is the primary competitor globally, with aggressive pricing and broad market access. Abbott has larger scale in international markets
• Pricing pressure — payer negotiations, OTC pricing for Stelo, and competitive dynamics may compress average selling prices over time
• Reimbursement risk — CGM coverage depends on government and commercial payer policies; changes in Medicare/Medicaid reimbursement could impact adoption
• Regulatory risk — FDA and international regulatory approvals required for new products and indications; delays could impact growth timeline
• Market expansion execution — success in Type 2 non-insulin and OTC markets is not guaranteed; consumer adoption patterns differ from prescription medical devices
• Technology disruption — non-invasive glucose monitoring technologies (optical, RF) could eventually disrupt needle-based CGM, though none have achieved comparable accuracy to date
• Patent litigation — ongoing intellectual property disputes with Abbott Diabetes Care
• Convertible debt — $1.24 billion in long-term senior convertible notes outstanding

Why Nasdaq-100

DexCom is a long-standing Nasdaq-100 constituent, reflecting its position as a high-growth medical technology company with a dominant market position in CGM:

• Market leadership — global #1 in CGM technology with 25+ years of pioneering innovation
• Recurring revenue — razor/blade model with sensors replaced every 10–15 days creates predictable, growing revenue streams
• Margin expansion — GAAP operating margin improved from ~15% to 21%+ in one year, with further expansion guided
• Large TAM expansion — moving from ~8.5M Type 1 patients to 400M+ Type 2 non-insulin users via OTC/Stelo
• Strong balance sheet — $2.42 billion in cash/securities, undrawn credit facility, $1B buyback program
• Consistent growth — revenue grew from ~$1.9B (FY2022) to $4.66B (FY2025), a ~35% CAGR

Sources

• Dexcom Reports First Quarter 2026 Financial Results (Apr 30, 2026) — investors.dexcom.com
• Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results (Feb 12, 2026) — investors.dexcom.com
• Nasdaq-100 Companies — nasdaq.com/solutions/global-indexes/nasdaq-100/companies
• Dexcom Investor Relations — investors.dexcom.com
• Dexcom Reports Preliminary Q4/FY2025 Results and 2026 Outlook (Jan 2026) — investors.dexcom.com